Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Preferred Shares (2016 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Preferred Shares for 8 consecutive years, with $2000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Preferred Shares fell 33.33% to $2000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $2000.0, a 33.33% decrease, with the full-year FY2025 number at $2000.0, down 33.33% from a year prior.
  • Preferred Shares was $2000.0 for Q4 2025 at Iovance Biotherapeutics, roughly flat from $2000.0 in the prior quarter.
  • In the past five years, Preferred Shares ranged from a high of $3000.0 in Q1 2023 to a low of $2000.0 in Q1 2025.
  • A 3-year average of $2500.0 and a median of $2500.0 in 2023 define the central range for Preferred Shares.
  • Peak YoY movement for Preferred Shares: changed 0.0% in 2024, then crashed 33.33% in 2025.
  • Iovance Biotherapeutics' Preferred Shares stood at $3000.0 in 2023, then changed by 0.0% to $3000.0 in 2024, then crashed by 33.33% to $2000.0 in 2025.
  • Per Business Quant, the three most recent readings for IOVA's Preferred Shares are $2000.0 (Q4 2025), $2000.0 (Q3 2025), and $2000.0 (Q1 2025).